Pia M Vuorela
Overview
Explore the profile of Pia M Vuorela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanski L, Kapp K, Tiirola T, Orav A, Vuorela H, Pussa T, et al.
Nat Prod Commun
. 2018 Nov;
11(11):1725-1728.
PMID: 30475517
The impact of solvent extracts from the distillation water (flavoring extracts) isolated from mint flavored candies on the infectivity of the intracellular bacterium Chlamydia pneumoniae was evaluated by an in...
2.
Skogman M, Vuorela P, Fallarero A
J Vis Exp
. 2017 Jan;
(118).
PMID: 28060302
Biofilms are regarded as one of the most challenging topics of modern biomedicine, and they are potentially responsible for over 80% of antibiotic-tolerant infections. Biofilms have displayed an exceptionally high...
3.
Skogman M, Kanerva S, Manner S, Vuorela P, Fallarero A
Molecules
. 2016 Sep;
21(9).
PMID: 27626397
Quorum sensing (QS) is the process by which bacteria produce and detect signal molecules to coordinate their collective behavior. This intercellular communication is a relevant target for anti-biofilm therapies. Here...
4.
Gupta S, Fallarero A, Vainio M, Saravanan P, Santeri Puranen J, Jarvinen P, et al.
Mol Inform
. 2016 Jul;
30(8):689-706.
PMID: 27467261
Recently discovered 42 AChE inhibitors binding at the catalytic and peripheral anionic site were identified on the basis of molecular docking approach, and its comparative quantitative structure-activity relationship (QSAR) models...
5.
Hanski L, Ausbacher D, Tiirola T, Strom M, Vuorela P
PLoS One
. 2016 Jun;
11(6):e0157306.
PMID: 27280777
We demonstrate in the current work that small cationic antimicrobial β2,2-amino acid derivatives (Mw < 500 Da) are highly potent against Chlamydia pneumoniae at clinical relevant concentrations (< 5 μM,...
6.
Fallarero A, Batista-Gonzalez A, Hiltunen A, Liimatainen J, Karonen M, Vuorela P
Int J Mol Sci
. 2015 Nov;
16(11):27044-57.
PMID: 26569236
Natural products are complex matrices of compounds that are prone to interfere with the label-dependent methods that are typically used for cytotoxicity screenings. Here, we developed a label-free Electric Cell-substrate...
7.
Manner S, Vahermo M, Skogman M, Krogerus S, Vuorela P, Yli-Kauhaluoma J, et al.
Eur J Med Chem
. 2015 Aug;
102:68-79.
PMID: 26241878
The combination of the dehydroabietic acid scaffold with different amino acids resulted in the discovery of a new class of hybrid compounds that targets both planktonic and biofilms bacteria in...
8.
Hakala E, Hanski L, Yrjonen T, Vuorela H, Vuorela P
Nat Prod Commun
. 2015 Jul;
10(6):1001-4.
PMID: 26197536
The purpose of this study was to investigate the effect and selectivity of an extract of Schisandra chinensis berries against Chlamydia pneumoniae and C. trachomatis. Among the ethnopharmacological uses of...
9.
Oja T, San Martin Galindo P, Taguchi T, Manner S, Vuorela P, Ichinose K, et al.
Antimicrob Agents Chemother
. 2015 Jul;
59(10):6046-52.
PMID: 26195520
Streptomyces bacteria are renowned for their ability to produce bioactive secondary metabolites. Recently, synthetic biology has enabled the production of intermediates and shunt products, which may have altered biological activities...
10.
Hanski L, Genina N, Uvell H, Malinovskaja K, Gylfe A, Laaksonen T, et al.
PLoS One
. 2014 Dec;
9(12):e115115.
PMID: 25514140
Given the established role of Chlamydia spp. as causative agents of both acute and chronic diseases, search for new antimicrobial agents against these intracellular bacteria is required to promote human...